• +1-646-491-9876
    • +91-20-67278686

    Search

    Acromegaly - Pipeline Review, H1 2017

    Acromegaly - Pipeline Review, H1 2017

    • Report Code ID: RW0001767469
    • Category Pharmaceuticals
    • No. of Pages 80
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Acromegaly - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H1 2017, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

    Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 8 and 3 respectively.

    Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Acromegaly - Overview
    Acromegaly - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Acromegaly - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Acromegaly - Companies Involved in Therapeutics Development
    Aegis Therapeutics LLC
    Amryt Pharma plc
    Antisense Therapeutics Ltd
    Chiasma Inc
    Crinetics Pharmaceuticals Inc
    Daewoong Pharmaceutical Co Ltd
    Dauntless Pharmaceuticals Inc
    DexTech Medical AB
    Foresee Pharmaceuticals LLC
    Glide Pharmaceutical Technologies Ltd
    Ionis Pharmaceuticals Inc
    Ipsen SA
    Italfarmaco SpA
    Midatech Pharma Plc
    Novartis AG
    Peptron Inc
    Silence Therapeutics Plc
    Strongbridge Biopharma plc
    Sun Pharma Advanced Research Company Ltd
    Acromegaly - Drug Profiles
    Antisense Oligonucleotide to Inhibit Growth Hormone Receptor for Acromegaly - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AP-102 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    atesidorsen sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BIM-23B065 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FP-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IONIS-GHRLRx - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ITF-2984 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    L-779976 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lanreotide SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate long acting - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide acetate SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    octreotide SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Somadex - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SXN-101959 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    veldoreotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Acromegaly - Dormant Projects
    Acromegaly - Discontinued Products
    Acromegaly - Product Development Milestones
    Featured News & Press Releases
    Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
    Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
    Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102
    Dec 02, 2016: Amryt Pharma provides update on AP-102
    Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly
    Sep 22, 2016: Aegis Awarded Patent for Non-Invasive Nasal Octreotide Formulation
    Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study
    Jul 13, 2016: ATL1103 Patent Update
    Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study
    Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa
    Jun 01, 2016: Antisense provides update on ATL1103 clinical trials
    May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
    May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI
    May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly
    Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Acromegaly, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Acromegaly - Pipeline by Aegis Therapeutics LLC, H1 2017
    Acromegaly - Pipeline by Amryt Pharma plc, H1 2017
    Acromegaly - Pipeline by Antisense Therapeutics Ltd, H1 2017
    Acromegaly - Pipeline by Chiasma Inc, H1 2017
    Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
    Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H1 2017
    Acromegaly - Pipeline by DexTech Medical AB, H1 2017
    Acromegaly - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
    Acromegaly - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
    Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
    Acromegaly - Pipeline by Ipsen SA, H1 2017
    Acromegaly - Pipeline by Italfarmaco SpA, H1 2017
    Acromegaly - Pipeline by Midatech Pharma Plc, H1 2017
    Acromegaly - Pipeline by Novartis AG, H1 2017
    Acromegaly - Pipeline by Peptron Inc, H1 2017
    Acromegaly - Pipeline by Silence Therapeutics Plc, H1 2017
    Acromegaly - Pipeline by Strongbridge Biopharma plc, H1 2017
    Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Acromegaly - Dormant Projects, H1 2017
    Acromegaly - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Acromegaly, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aegis Therapeutics LLC
    Amryt Pharma plc
    Antisense Therapeutics Ltd
    Chiasma Inc
    Crinetics Pharmaceuticals Inc
    Daewoong Pharmaceutical Co Ltd
    Dauntless Pharmaceuticals Inc
    DexTech Medical AB
    Foresee Pharmaceuticals LLC
    Glide Pharmaceutical Technologies Ltd
    Ionis Pharmaceuticals Inc
    Ipsen SA
    Italfarmaco SpA
    Midatech Pharma Plc
    Novartis AG
    Peptron Inc
    Silence Therapeutics Plc
    Strongbridge Biopharma plc
    Sun Pharma Advanced Research Company Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//acromegaly-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//acromegaly-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//acromegaly-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments